Synovial sarcoma
MONDO:0010434Synovial sarcoma is an aggressive soft tissue sarcoma, occurring most commonly in adolescents and young adults (15 to 40 years), usually localized near the large joints of the extremities but also in the head and neck, mediastinum and viscera (lung, kidney etc), clinically presenting as a deep seated swelling or a painful mass often with an initial indolent course and is characterized by its local invasiveness and a propensity to metastasize. The origin of synovial sarcoma is likely from multipotent mesenchymal cells and not synovium (contrary to its name).
Also known as: SS, Synovialosarcoma, sarcoma, synovial, malignant, synovial sarcoma, synovial sarcoma (disease), sarcoma, synovial
2854 clinical trials for this condition and its sub-types, 53 tagged with Synovial sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Synovial sarcoma
-
Biphasic synovial sarcoma 0 trials
-
Breast synovial sarcoma 0 trials
-
Fibrous synovial sarcoma 0 trials
-
Mediastinum synovial sarcoma 0 trials
-
Monophasic synovial sarcoma 0 trials
2 sub-types
- Epithelioid cell synovial sarcoma 0 trials
- Spindle cell synovial sarcoma 0 trials
-
Designer immune cells take on rare sarcomas
Disease control CompletedThis phase 2 trial tests a personalized cell therapy called Lete-Cel in 7 people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not been treated before. Participants receive their own immune cells that have been engineered to recognize and attack their c…
Phase 2 • Sponsor: USWM, LLC (dba US WorldMeds) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Engineered immune cells take on rare sarcomas in new trial
Disease control CompletedThis phase 2 trial tests a treatment called Lete-Cel, which uses a patient's own immune cells that have been specially trained to attack cancer cells. It is for people with advanced synovial sarcoma or myxoid/round cell liposarcoma whose tumors have a specific marker (NY-ESO-1) a…
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill may keep soft tissue sarcoma in check after chemo
Disease control CompletedThis study tested whether taking anlotinib pills after initial chemotherapy can help keep advanced soft tissue sarcoma from growing. 49 adults with certain types of sarcoma took anlotinib daily. The goal was to see how long the cancer stayed stable and to check safety. Anlotinib …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy boosts chemo against rare sarcomas?
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and w…
Phase 2 • Sponsor: Alexander Z. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Personalized chemo shows promise against rare sarcomas
Disease control CompletedThis Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…
Phase 3 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase 1/2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a simple test predict who will respond to this sarcoma drug?
Knowledge-focused CompletedThis study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC